Publications associées à Sel de platine

Urtica dioica Leaf Infusion Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Cisplatin Treatment

Urtica dioica (UD) has been widely used in traditional medicine due to its therapeutic benefits, including its anticancer effects. Natural compounds have a promising potential when used in combination with chemotherapeutic drugs. The present study explores ...

MDPI2023

Structural Basis of the Allosteric Inhibition of Human ABCG2 by Nanobodies

Henning Paul-Julius Stahlberg, Dongchun Ni

ABCG2 is an ATP-binding cassette transporter that exports a wide range of xenobiotic compounds and has been recognized as a contributing factor for multidrug resistance in cancer cells. Substrate and inhibitor interactions with ABCG2 have been extensively ...

Academic Press Ltd- Elsevier Science Ltd2023

Optimised three-dimensional in vitro retinoblastoma models tailored for drug discovery and clinical translatability

Irina Sinenko

Retinoblastoma, while relatively rare, stands as the most prevalent intraocular cancer. In Switzerland, the survival rate approaches 100%, but it drops to less than 50% in low-income countries. The current treatment options for retinoblastoma rely on a lim ...

EPFL2023

Discovery and Development of Hyperthermia-Enhanced Treatments for Malignant Skin and Uveal Melanomas

Mouna Hadiji

Melanomas are among the deadliest cancers, with a high predisposition to metastasis and a bad prognosis in their late stages. The effectiveness of current therapeutic regimens remains suboptimal, and despite initial successes, treatment resistance emerges ...

EPFL2023

Photoresponsive Nanocarriers Based on Lithium Niobate Nanoparticles for Harmonic Imaging and On-Demand Release of Anticancer Chemotherapeutics

Sandrine Gerber, Jérémy Vuilleumier, Adrian Stefan Gheata, Dario Diviani, Luigi Bonacina, Simon Kaiser

Nanoparticle-based drug delivery systems have the potential for increasing the efficiency of chemotherapeutics by enhancing the drug accumulation at specific target sites, therebyreducing adverse side effects and mitigating patient acquired resistance. In ...

2022

Assessment of metal-based dihydrofolate reductase inhibitors on a novel mesofluidic platform

Paul Joseph Dyson, Sarah Alexandra Pais Pereira

A new miniaturized micro sequential injection coupled with the lab-on-valve (mu SIA-LOV) technique was full-blown to perform inhibitory studies on dihydrofolate reductase (DHFR). The system was used to evaluate the DHFR inhibition activity of metal-based a ...

ELSEVIER SCIENCE SA2022

Photocontrolled release of the anticancer drug chlorambucil with caged harmonic nanoparticles

Sandrine Gerber, Jean-Pierre Wolf, Jérémy Vuilleumier, Raphaël Jovita De Matos, Luigi Bonacina

While chemotherapy is one of the most used treatments in oncology, the systemic administration of chemotherapeutics generally results in undesired damages to healthy tissues and cells, side effects such as severe nausea and leukopenia, and reduced efficacy ...

Wiley-VHCA AG2020

T cell force-responsive delivery of anticancer drugs using mesoporous silica microparticles

Li Tang, Kewen Lei

T cell-based cancer immunotherapy has achieved great success in the clinic; however, only a small fraction of patients respond to this therapy. Strategies to specifically and safely augment anticancer activity through controlled delivery of T cell supporti ...

2020

Computational characterisation of the selectivity and binding mode of mono- and binuclear transition metal based anticancer compounds

Thibaud Edouard Alistair von Erlach

The rising resistance and the severe side effects associated with classical anticancer drugs such as cisplatin or mercaptopurines has triggered the development of novel antitumourous agents based on transition metal (e.g. ruthenium, osmium, and gold) organ ...

EPFL2020

Classification of Metal-Based Drugs according to Their Mechanisms of Action

Paul Joseph Dyson

Metal-based drugs and imaging agents are extensively used in the clinic for the treatment and diagnosis of cancers and a wide range of other diseases. The current clinical arsenal of compounds operate via a limited number of mechanisms, whereas new putativ ...

CELL PRESS2020